期刊
BJU INTERNATIONAL
卷 110, 期 11, 页码 1580-1588出版社
WILEY
DOI: 10.1111/j.1464-410X.2012.11445.x
关键词
prostate cancer; castration resistance; androgen deprivation; novel endocrine therapy; hormone refractory; androgen receptor
资金
- Millenium
Despite undergoing local therapy with curative intent, 20-30% of patients with prostate cancer will ultimately development metastatic disease, leading to morbidity and mortality. Androgen-deprivation therapy (ADT) for men with metastatic prostate cancer results in transient clinical benefit, but ultimately, cancers progress despite castrate levels of serum testosterone, a clinical state classically referred to as 'hormone refractory' disease. In this review, we examine mechanisms of resistance to ADT that have redefined our understanding of the more appropriately termed 'castration resistant' disease, and have paved the way for a new generation of therapeutics targeting the androgen signalling axis in advanced prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据